Maminata Traore / Coulibaly

Current Job Biologist Researcher
Personal Statement I am a Biomedical Researcher and the Director of Research in Biochemistry (Natural Products Chemistry) and Microbiology.
I Studied at University of Ouagadougou, Burkina Faso and Danish Faculty of Pharmaceutical Sciences, University of Copenhagen.
My research activities are focused on infectious diseases:
– preclinical and clinical evaluation of medicines and phytomedicines
– Biochemistry (Natural Products Chemistry).
I Have achieved around 15 founded projects as investigator or co-investigator and auteur of more than 65 publications and one patent.
Education 2008: PhD in Pharmaceutical Sciences / Chemistry of natural products, University of Copenhagen, Denmark
1996: Doctorate of 3rd cycle in Applied Biological Sciences, Biochemistry and Microbiology, University of Ouagadougou, Burkina Faso
1992: DEA in Applied Biological Sciences, Biochemistry and Microbiology, University of Ouagadougou, Burkina Faso
1990: Masters in Applied Biological Sciences, Animal Biology and Physiology, University of Ouagadougou, Burkina Faso
1989: Bachelor in Applied Biological Sciences, Chemistry-Biology, University of Ouagadougou, Burkina Faso
Experiences Academic Position:
– CAMES Director of Research, since 2018
– Teacher at Catholic University (UCAO) in Bobo-Dioulasso, Burkina Faso and at University Nazi Boni
– Supervision of PhD, Master, Pharmacy and Medicine theses, around 20.
Administrative position:
– Deputy ministry of Research and Innovation, MESRSI, Burkina Faso
– Scientific Director of the Regional Direction of IRSS, based at the Clinical Research Unit of Nanoro, 2016-2021
– Head of the Department “Studies and Monitoring-Evaluation” 2014-2016
– Head of the Department “Studies and Planning”, 2013-2014
– Member of AVAREF/OMS technical committee, 2016-2020
– Member of the health ethics committee (CERS), 2013-2020
Awards / Honors – Knight of the Order of Academic Palms
– Prize for the best posters (1st and 2nd prize), WANPRES 2012 in Nigeria
Research Grants Grants obtained:
1. 2020-2023 Portfolio approach to developing the next generation of malaria treatments for Africa Phase II EDCTP
2. 2019-2021 : A Phase Ib/IIb randomised controlled trial of the safety, immunogenicity and efficacy of a candidate malaria vaccine, R21 adjuvanted with Matrix-M (R21/MM), in 5-17 months old children in Nanoro, Burkina Faso Phase II EDCTP
3. 2018-2023: Field efficacy testing of a malaria vaccine targeting all four stages of the parasite’s life-cycle Phase II EDCTP
4. 2019-2024: Safety and Efficacy of a newly registered Artemisin-Based Combination (Pyronaridine-Artesunate – PYRAMAX®) for the treatment of uncomplicated malaria in African pregnant women Phase III EDCTP
5. 2016-2017: Phase IV study to evaluate the effectiveness of the fixed-dose artemisinin-based combination therapy Pyramax ® (Pyronaridine-artesunate) in uncomplicated malaria patients in the Nanoro Health District, Burkina Faso Phase IV INDEPTH / Gates Foundation
6. 2016-2020: Pre-delivery administration of azithromycin to prevent neonatal sepsis and death: a phase III double-blind randomized clinical trial Phase III DFID/MRC, UK
7. 2016-2019: A comparative trial of seasonal vaccination with the malaria vaccine RTS,S/AS01, seasonal malaria chemoprevention and of the two interventions combined Phase III DFID/MRC, UK
8. 2015-2017: Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa Phase III GlaxoSmithKline (GSK)
alternatetext PubMed Link
alternatetext ORCID Link
alternatetext Publons Link Publons Link
alternatetext ResearchGate Link
alternatetext Twitter Link
Click to rate!
[Total: 0 Average: 0]